glp-1 description A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes and obesity, including cardiovascular disease and neurodegenerative disorders File:GLP-1 Signaling in the Body.jpg

For selected patients, semaglutide has also become part of the cardiovascular-risk conversation because Wegovy has an FDA-approved indication to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight

GLP-1 GLP-1 NAION GLP-1

As use continues to grow, emergency physicians will encounter these medications more frequently across a broader patient population

Understanding how many calories to eat on semaglutide and how many calories to eat on tirzepatide becomes critical groundwork before adding a fasting protocol